https://youtu.be/ZZNGEHlRimc Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q4 FY22 Earnings Concall Management Update: AUROPHARMA received final approval for 3 ANDAs and
(AUROPHARMA)
XNSE:AUROPHARMA, XBOMAUROPHARMA
Aurobindo Pharma Ltd (AUROPHARMA) Q4 FY22 Earnings Concall Transcript
Aurobindo Pharma Ltd (NSE: AUROPHARMA) Q4 FY22 Earnings Concall dated May 30, 2022 Corporate Participants: Deepthi Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer
Aurobindo Pharma Q3 FY 2022 Research Tear Sheet
Aurobindo Pharma Limited is an Indian pharmaceutical company. It is based in HITEC City, Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include
Aurobindo Pharma Limited (AUROPHARMA) Q3 FY22 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE :AUROPHARMA) Q3 2022 Earnings Concall Feb. 10, 2022, Corporate Participants: Arvind Bothra -- Investor Relations Department Santhanam Subramanian
Earnings: Aurobindo Pharma results in Q2 2022
Aurobindo Pharma (NSE: AUROPHARMA) reported its second-quarter 2022 earnings results today. The company had a consolidated net profit of ₹696.71 crores with
Aurobindo Pharma Ltd (AUROPHARMA) Q3 FY21 Earnings Concall Transcript
Aurobindo Pharma Ltd (NSE:AUROPHARMA) Q3 FY21 earnings concall dated Feb. 10, 2021. Corporate Participants: Krishna Kiran -- Manager of Investor Relations Santhanam